Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Group 1 - The company has experienced significant growth in its DNA Synthesis and Protein Solutions segments, with a year-over-year increase of 27% in Q1 [2] - The traditional drug discovery process involves in vivo/in vitro methods, where DNA is extracted from inoculated mice to screen for novel antibodies [3] - The company utilizes a large library of over 10 billion antibodies, employing phage display techniques to identify and characterize 10 to 100 antibodies for customer use [3] Group 2 - The resegmentation into SynBio and Protein Solutions is a key focus area for the company, indicating a strategic shift to capitalize on emerging trends in the industry [1] - The company is positioned as a leader in AI applications within its sector, although it does not utilize a specific AI plug-in like Claude [1]